MA28579B1 - Dérivés de tétrahydronaphtyridine utiles comme ligands du récepteur d'histamine H3 - Google Patents

Dérivés de tétrahydronaphtyridine utiles comme ligands du récepteur d'histamine H3

Info

Publication number
MA28579B1
MA28579B1 MA29447A MA29447A MA28579B1 MA 28579 B1 MA28579 B1 MA 28579B1 MA 29447 A MA29447 A MA 29447A MA 29447 A MA29447 A MA 29447A MA 28579 B1 MA28579 B1 MA 28579B1
Authority
MA
Morocco
Prior art keywords
histamine
receptor ligands
derivatives useful
tetrahydronaphthyridine derivatives
tetrahydronaphthyridine
Prior art date
Application number
MA29447A
Other languages
English (en)
Inventor
Graham Lunn
John Paul Mathias
Ross Sinclair Strang
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA28579B1 publication Critical patent/MA28579B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
MA29447A 2004-05-12 2006-11-10 Dérivés de tétrahydronaphtyridine utiles comme ligands du récepteur d'histamine H3 MA28579B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04291222A EP1595881A1 (fr) 2004-05-12 2004-05-12 Dérivés de tetrahydronaphthyridine en tant que ligands de récepteur H3 d'histamine

Publications (1)

Publication Number Publication Date
MA28579B1 true MA28579B1 (fr) 2007-05-02

Family

ID=34931096

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29447A MA28579B1 (fr) 2004-05-12 2006-11-10 Dérivés de tétrahydronaphtyridine utiles comme ligands du récepteur d'histamine H3

Country Status (32)

Country Link
US (2) US7557121B2 (fr)
EP (2) EP1595881A1 (fr)
JP (1) JP4084410B2 (fr)
KR (1) KR100908155B1 (fr)
CN (2) CN101798305A (fr)
AP (1) AP2006003786A0 (fr)
AR (1) AR049092A1 (fr)
AT (1) ATE491707T1 (fr)
AU (1) AU2005243403B2 (fr)
BR (1) BRPI0510762A (fr)
CA (1) CA2564201C (fr)
CR (1) CR8747A (fr)
DE (1) DE602005025345D1 (fr)
DK (1) DK1756104T3 (fr)
EA (1) EA010487B1 (fr)
EC (1) ECSP066984A (fr)
ES (1) ES2355572T3 (fr)
GE (1) GEP20084552B (fr)
GT (1) GT200500112A (fr)
IL (1) IL178882A (fr)
MA (1) MA28579B1 (fr)
MX (1) MXPA06013113A (fr)
NL (1) NL1029016C2 (fr)
NO (1) NO20064577L (fr)
PA (1) PA8632801A1 (fr)
PE (1) PE20060312A1 (fr)
SV (1) SV2005002112A (fr)
TN (1) TNSN06369A1 (fr)
TW (1) TW200607506A (fr)
UY (1) UY28895A1 (fr)
WO (1) WO2005111036A1 (fr)
ZA (1) ZA200609111B (fr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6468306B1 (en) 1998-05-29 2002-10-22 Advanced Medical Optics, Inc IOL for inhibiting cell growth and reducing glare
US7621949B2 (en) 2003-12-09 2009-11-24 Advanced Medical Optics, Inc. Foldable intraocular lens and method of making
DE602006002894D1 (de) 2005-06-17 2008-11-06 Janssen Pharmaceutica Nv Naphthyridinverbindungen
US8158673B2 (en) 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
EP1945639A1 (fr) * 2005-11-04 2008-07-23 Pfizer Limited Dérivé de tétrahydronaphtyridine
WO2007099423A1 (fr) * 2006-03-02 2007-09-07 Pfizer Products Inc. Dérivés de 1-pyrrolidine indane en tant qu'antagonistes du récepteur d'histamine 3
JP2009531314A (ja) 2006-03-10 2009-09-03 ニューロジェン・コーポレーション ピペラジニルオキソアルキルテトラヒドロイソキノリン類および関連類似物
CA2655604C (fr) 2006-06-23 2016-08-09 Abbott Laboratories Derives de cyclopropylamine
US9108948B2 (en) 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
EP2216023A4 (fr) * 2007-11-15 2013-03-13 Takeda Pharmaceutical Dérivé de pyridine condensé et son utilisation
WO2009082698A1 (fr) * 2007-12-21 2009-07-02 Abbott Laboratories Compositions pour le traitement de troubles cognitifs
US8383657B2 (en) 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
EA201001329A1 (ru) * 2008-02-22 2011-04-29 Айрм Ллк Соединения и композиции в качестве модуляторов активности gpr119
JP2011518127A (ja) * 2008-03-31 2011-06-23 エヴォテック・アクチエンゲゼルシャフト ヒスタミンｈ３受容体アンタゴニストとしてのテトラヒドロナフチリジンおよびそれらのアザ誘導体
WO2010026113A1 (fr) * 2008-09-03 2010-03-11 Evotec Neurosciences Gmbh Acyl- et sufonyl-tétrahydronaphtyridines et dérivés aza de celles-ci en tant qu’antagonistes de récepteur d’histamine h3
WO2010052222A1 (fr) * 2008-11-07 2010-05-14 Evotec Neurosciences Gmbh Dérivés (dihydro)naphthyridinone comme antagonistes du récepteur h3 de l’histamine
EP2421863A1 (fr) * 2009-04-21 2012-02-29 NeuroSearch AS Dérivés de naphtyridine substitués et leur utilisation médicale
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
US8711772B2 (en) * 2009-05-22 2014-04-29 Qualcomm Incorporated Paging of a user equipment (UE) within a wireless communications system
US20120101106A1 (en) * 2009-07-09 2012-04-26 Mercer Swati P Tetrahydronapthyridine Orexin Receptor Antagonists
WO2012037258A1 (fr) 2010-09-16 2012-03-22 Abbott Laboratories Procédés de préparation de dérivés cyclopropyliques substitués en 1,2
CN102093356B (zh) * 2011-03-16 2012-12-19 无锡美克赛医药科技有限公司 一种2-氯-5,6,7,8-四氢-1,6-萘啶盐酸盐的制备方法
WO2012131539A1 (fr) 2011-03-31 2012-10-04 Pfizer Inc. Nouvelles pyridones bicycliques
WO2012172449A1 (fr) 2011-06-13 2012-12-20 Pfizer Inc. Lactames convenant comme inhibiteurs des bêta-sécrétases
JP6043355B2 (ja) 2011-08-31 2016-12-14 ファイザー・インク ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
ES2585262T3 (es) 2012-05-04 2016-10-04 Pfizer Inc Compuestos heterocíclicos de hexahidropiran[3,4-d][1,3]tiazin-2-amina sustituidos como inhibidores de PPA, BACE1 y BACE2
MD20140130A2 (ro) 2012-06-29 2015-04-30 Pfizer Inc. 4-(amino-substituite)-7H-pirolo[2,3-d]pirimidine noi ca inhibitori de LRRK2
CA2882389A1 (fr) 2012-09-20 2014-03-27 Pfizer Inc. Composes d'hexahydropyrano[3,4-d][1,3]thiazine-2-amine alkyl-substitues
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
WO2014091352A1 (fr) 2012-12-11 2014-06-19 Pfizer Inc. Composés d'hexahydropyrano [3,4-d][1,3]thiazin-2-amine en tant qu'inhibiteurs de bace1
CA2893333C (fr) 2012-12-19 2017-10-24 Pfizer Inc. Composes hexahydropyrano[3,4-d][1,3]thiazin-2-amine substitues carbocycliques et heterocycliques
WO2014125394A1 (fr) 2013-02-13 2014-08-21 Pfizer Inc. Composés hexahydropyrano [3,4-d][1,3] thiazin-2-amine substitués par un hétéroaryle
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
AP2015008663A0 (en) 2013-02-19 2015-08-31 Pfizer Azabenzimidazole compounds as inhibitors of PDE4 isozymes for the treatment of cns and other disorders
AP2015008843A0 (en) 2013-05-02 2015-11-30 Pfizer Imidazo-triazine derivatives as pde10 inhibitors
CA2925743C (fr) 2013-10-04 2018-03-06 Pfizer Inc. Nouvelles pyridinones bicycliques utilisees comme modulateurs de gamma-secretase
WO2015092592A1 (fr) 2013-12-17 2015-06-25 Pfizer Inc. Nouvelles 1h-pyrrolo[2,3- b]pyridines 3,4-disubstituées et 7h-pyrrolo[2,3-c]pyridazines 4,5-disubstituées en tant qu'inhibiteurs de la lrrk2
PE20161364A1 (es) 2014-04-01 2016-12-25 Pfizer CROMENO Y 1,1a,2,7b-TETRAHIDROCICLOPROPA [C] CROMENO PIRIDOPIRAZINADIONAS NOVEDOSAS
CR20160455A (es) 2014-04-10 2016-12-16 Pfizer 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILA
EP3172210B1 (fr) 2014-07-24 2020-01-15 Pfizer Inc Composés de pyrazolopyrimidine
SG11201700243YA (en) 2014-08-06 2017-02-27 Pfizer Imidazopyridazine compounds
TN2017000342A1 (en) 2015-02-03 2019-01-16 Pfizer Novel cyclopropabenzofuranyl pyridopyrazinediones
KR20180011272A (ko) * 2015-05-28 2018-01-31 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 키나제 저해제로서 나프티리딘 화합물
ES2832893T3 (es) 2015-06-17 2021-06-11 Pfizer Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa
CN108137586B (zh) 2015-09-14 2021-04-13 辉瑞大药厂 作为LRRK2抑制剂的新颖咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啶衍生物
EP3353174A1 (fr) 2015-09-24 2018-08-01 Pfizer Inc N-[2-(3-amino-2,5-diméthyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl]amides utiles comme inhibiteurs de bace
WO2017051276A1 (fr) 2015-09-24 2017-03-30 Pfizer Inc. N-[2-(2-amino-6,6-disubstitués-4,4a,5,6-tétrahydropyrano[3,4-d][1,3]thiazin-8a(8h)-yl)-1,3-thiazol-4-yl]amides
JP2018531924A (ja) 2015-09-24 2018-11-01 ファイザー・インク テトラヒドロピラノ［３，４−ｄ］［１，３］オキサジン誘導体、およびｂａｃｅ阻害剤としてのその使用
PL3419979T3 (pl) 2016-02-23 2020-06-29 Pfizer Inc. Związki 6,7-dihydro-5h-pirazolo[5,1-b][1,3]oksazyno-2- karboksyamidowe
HUE054857T2 (hu) 2016-07-01 2021-10-28 Pfizer 5,7-dihidro-pirrolo-piridinszármazékok neurológiai és neurodegeneratív betegségek kezelésére
WO2018163066A1 (fr) 2017-03-10 2018-09-13 Pfizer Inc. Nouveaux dérivés imidazo[4,5-c]quinoléine utilisés en tant qu'inhibiteurs de lrrk2
WO2018163030A1 (fr) 2017-03-10 2018-09-13 Pfizer Inc. Dérivés d'imidazo [4,5-c] quinoléine substitués cycliques
EP3634978A1 (fr) 2017-06-07 2020-04-15 Adrx, Inc. Inhibiteur d'agrégation de tau
CN110944998B (zh) 2017-06-22 2022-08-16 辉瑞大药厂 二氢-吡咯并-吡啶衍生物
EP3668886A2 (fr) 2017-08-18 2020-06-24 Adrx, Inc. Inhibiteurs peptidiques d'agrégation de tau
ES2942837T3 (es) 2018-03-23 2023-06-07 Pfizer Derivados de azaespiro piperazina
WO2022182658A1 (fr) 2021-02-23 2022-09-01 Hoth Therapeutics, Inc. Utilisation d'aprépitant pour le traitement de la maladie d'alzheimer
KR20240012534A (ko) * 2021-05-21 2024-01-29 청두 바이위 파머수티컬 씨오., 엘티디 피페라진 유도체 및 이의 의학적 용도
WO2025145091A1 (fr) 2023-12-29 2025-07-03 Pfizer Inc. Formes cristallines d'un modulateur muscarinique m4 du récepteur et méthodes de traitement de maladies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
AU709611B2 (en) 1996-02-09 1999-09-02 James Black Foundation Limited Histamine h3 receptor ligands
WO2000035298A1 (fr) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing-gum contenant des agents medicamenteux actifs
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
GB9803536D0 (en) * 1998-02-19 1998-04-15 Black James Foundation Histamine H,receptor ligands
EP0982300A3 (fr) 1998-07-29 2000-03-08 Societe Civile Bioprojet Non-imidazole alkylamines comme antagonistes du recepteur histamine H3 et leur application thérapeutique
TWI298068B (en) * 2000-06-21 2008-06-21 Dainippon Sumitomo Pharma Co Pharmaceutical composition for schizophrenia
JP4516717B2 (ja) 2000-07-13 2010-08-04 アボット・ラボラトリーズ ヒスタミン−３受容体リガンドとしての１，３−二置換ピロリジン及び１，３，３−三置換ピロリジン並びにそれらの治療的応用
KR100852362B1 (ko) 2000-08-08 2008-08-14 오르토-맥네일 파마슈티칼, 인코퍼레이티드 비-이미다졸 아릴옥시피페리딘
ATE319696T1 (de) * 2000-08-08 2006-03-15 Ortho Mcneil Pharm Inc Nicht-imidazol aryloxyalkylamine als h3 rezeptor liganden
WO2002076925A2 (fr) 2001-03-23 2002-10-03 Eli Lilly And Company Composes d'aryl alkylamines non imidazole comme antagonistes des recepteurs h3 de l'histamine, preparation et applications therapeutiques
GB0206033D0 (en) * 2002-03-14 2002-04-24 Pfizer Ltd Compounds useful in therapy
CA2532236C (fr) * 2003-07-29 2011-08-23 Novo Nordisk A/S Pyridazinyl-piperazines et leur utilisation en tant que ligands du recepteur histaminique h3
EP1945639A1 (fr) * 2005-11-04 2008-07-23 Pfizer Limited Dérivé de tétrahydronaphtyridine

Also Published As

Publication number Publication date
DE602005025345D1 (de) 2011-01-27
EP1756104B1 (fr) 2010-12-15
DK1756104T3 (da) 2011-02-21
US20090258861A1 (en) 2009-10-15
CR8747A (es) 2006-12-05
EP1595881A1 (fr) 2005-11-16
ATE491707T1 (de) 2011-01-15
NO20064577L (no) 2006-11-06
KR100908155B1 (ko) 2009-07-16
WO2005111036A1 (fr) 2005-11-24
TW200607506A (en) 2006-03-01
IL178882A0 (en) 2007-03-08
GEP20084552B (en) 2008-11-25
UY28895A1 (es) 2005-12-30
JP2007536374A (ja) 2007-12-13
ECSP066984A (es) 2006-12-29
CA2564201A1 (fr) 2005-11-24
CN1950371A (zh) 2007-04-18
EP1756104A1 (fr) 2007-02-28
US20050256135A1 (en) 2005-11-17
CA2564201C (fr) 2011-01-18
KR20070014174A (ko) 2007-01-31
US7557121B2 (en) 2009-07-07
JP4084410B2 (ja) 2008-04-30
NL1029016C2 (nl) 2006-05-30
NL1029016A1 (nl) 2005-11-15
BRPI0510762A (pt) 2007-11-20
CN101798305A (zh) 2010-08-11
PA8632801A1 (es) 2006-06-02
PE20060312A1 (es) 2006-05-03
EA010487B1 (ru) 2008-10-30
AU2005243403A1 (en) 2005-11-24
MXPA06013113A (es) 2007-02-28
AP2006003786A0 (en) 2006-10-31
ZA200609111B (en) 2008-08-27
CN1950371B (zh) 2011-01-12
SV2005002112A (es) 2005-12-13
TNSN06369A1 (fr) 2008-02-22
AR049092A1 (es) 2006-06-28
EA200601897A1 (ru) 2007-02-27
ES2355572T3 (es) 2011-03-29
AU2005243403B2 (en) 2010-10-07
IL178882A (en) 2011-03-31
GT200500112A (es) 2005-12-12

Similar Documents

Publication Publication Date Title
AP2006003786A0 (en) Tetrahydronaphthyridine derivatives useful as histamine H3 receptor ligands
MA28391B1 (fr) Dérivés de 3-cycloalkylaminopyrrolidine utiles comme modulateurs de récepteurs de chimiokines
DK1797099T3 (da) Piperidinylamino-thieno[2,3-D]pyrimidinforbindelser
EP1613961A4 (fr) Complexes de recepteurs de surface utilises comme biomarqueurs
EP1937825A4 (fr) 4'-nucleosides modifies utiles comme agents antiviraux
EP2103619A4 (fr) Dérivés d'imidazothiazole
MA28798B1 (fr) Dérivés de triazolopyridinylsufanyle servant d'inhibiteurs de kinase MAP P38
EP2032566A4 (fr) Dérivés d'azétidine comme inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase
IL174400A0 (en) Substituted diazabicycloalkane derivatives as ligands at alpha 7 nicotinic acety lcholine receptors
ZA200700683B (en) Piperidine derivatives as histamine H3 receptor ligands
ZA200806071B (en) Sulfonyl substituted 1H-indoles as ligands for the 5-hydroxytryptamine receptors
SI1710241T1 (sl) Intermediatne spojine za pripravo trans-5-kloro-2-metil-2,3,3a, 12b-tetrahidro-1H-dibenz(2,3:6,7)oksepino(4,5-C)pirola
EP2138484A4 (fr) Dérivés d'hétéro-aryle bicyclique fusionnés
EP1951061A4 (fr) Méthode de modification de la texture d'une préparation
DK1802307T3 (da) Pyrrolidinderivater som histamin-receptor-ligander
EP1810969A4 (fr) Dérivés de benzimidazole aryloxy-substitués
EP1951231A4 (fr) Derives de camptothecine utiles comme agents chimioradiosensibles
ATE306265T1 (de) Benzothiazolderivate als adenosin-rezeptor- liganden
FR2875971B1 (fr) Convertisseur alternatif-continu pour l'aeronautique
DE60305058D1 (de) Imidazoquinoline derivate als adenosine a3 rezeptor liganden
EP1750351A4 (fr) Alternateur pour véhicule
DK1838683T3 (da) Fremgangsmåde til fremstilling af [1,4,5]-oxadiazepinderivater
EP1714656A4 (fr) Preparation de l'ed-71
SI1636223T1 (sl) Derivati benzotiazola kot ligandi receptorja adenozina
EP1786433A4 (fr) Derives de betulinol utilises en tant qu'agents anti-vih